Fluorescent Amyloid Binding Agents for Diagnosis of Alzheimer's Disease
Fluorescent Amyloid Binding Agents for Diagnosis of Alzheimer's Disease
A common structural feature of known amyloid-binding agents is an electronically-polarized, extended aromatic system that is inherent to a family of fluorescent probes known as molecular rotors. Features of molecular rotors, which inherently decrease the
San Diego, CA, United States
Overview Comments Tagged publications

Background

Amyloids are insoluble fibrous protein aggregates that accumulate in various organs throughout the human body. It has been clinically proven that abnormal accumulation of beta-amyloids in the brain is associated with various neurodegenerative diseases, including Alzheimer disease. Diagnostic biomarkers currently in clinical development are limited to small radio-labeled molecules for detection of amyloidosis through PET or SPECT imaging modes. There remains a pressing need for the design and development of new imaging agents for conclusive early diagnosis of Alzheimer’s disease, ideally through widely accessible detection platforms.


Technology Description

A common structural feature of known amyloid-binding agents is an electronically-polarized, extended aromatic system that is inherent to a family of fluorescent probes known as molecular rotors. Features of molecular rotors, which inherently decrease the non-radiative decay rate and increase fluorescence emission upon binding to aggregated beta-amyloids, were incorporated into a general design of novel, amyloid-binding agents.


Applications

  • Fluorescent probes are compatible with in vivo fluorescence imaging instruments. 
  • Generally relevant for the early diagnosis of diseases characterized by amyloid aggregates, such as Alzheimer’s, Parkinson, Huntington disease, and rheumatoid arthritis. 

 

Advantages

  • Simple synthesis and chemistries amenable to modification and production at large scales. 
  • Fluorescence profile optimized for in vivo characterization of amyloid deposits using existing and widely accessible imaging instruments. 
  • These probes may be used for the monitoring of disease progression in the development of new therapeutic treatments. 

 

State Of Development

Proprietary methods were used to identify, synthesize, and characterize seven, novel compositions of matter. Development included in vitro evaluation for specifications relevant to use in clinical practice, including: solubility, fluorescence characteristics, ability to cross the blood-brain barrier, binding constants, and capability to detect amyloidosis in brain tissue.


Related Materials

No comments.
No tagged publications.

Similar innovations

Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
← Previous Next → 1 2 3 4 Last
Showing 1-4 from 48

Send Us a Message